Articles tagged with Pancreatic Cancer
A Cardiff University-led study has discovered a protein, calmodulin, that protects pancreatic cells against the harmful effects of alcohol. The findings could lead to the development of new treatments for pancreatitis and reduce the risk of pancreatic cancer.
Researchers at Dana-Farber Cancer Institute have found that a malaria drug, hydroxychloroquine, can slow the growth of pancreatic tumors in mice. The oral drug has been shown to decrease tumor growth by inhibiting autophagy, a survival strategy used by cancer cells.
A long-term study found that consuming three or more drinks a day is associated with an increased risk of pancreatic cancer death in both men and women. Heavy drinking, specifically liquor consumption, also shows a significant association with pancreatic cancer mortality, particularly among never smokers.
A University of Georgia research team found that modifying a cell-surface protein called CNT1 can increase the effectiveness of gemcitabine, a common drug used to treat pancreatic cancer. By improving CNT1 function, researchers can help carry the drug into tumor cells and prevent proliferation.
Researchers identified specific genetic mutations that predict tumor aggressiveness and treatment response in patients with neuroendocrine pancreatic cancer. The study's findings could lead to personalized cancer therapy and improved patient outcomes.
A team of researchers has made a discovery about how the Ras oncogene chooses a signaling pathway and its consequences in cellular development, a key issue in cancer. The study used a common roundworm, C. elegans, to identify the critical events leading to pancreatic cancer.
A study published in Science reveals that satellite repeats, previously thought to be inactive, are actively expressed in many types of epithelial cancers. This discovery may lead to the development of a new cancer biomarker for early detection and improved understanding of tumor behavior.
Researchers at The Peggy and Charles Stephenson Oklahoma Cancer Center have found a way to stop early stage pancreatic cancer in research models, offering a promising approach for high-risk patients. A clinical trial has been launched, and the FDA-approved drug Gefitinib is expected to be tested nationwide within a year.
The 2010 Golf Atlanta charity golf tournament raised $105,000 to support investigations into pancreatic cancer at The Translational Genomics Research Institute. The event drew 124 players and included a high-end auction with donations supporting TGen's life-changing research.
A study published in Cancer Prevention Research found that gefitinib reduced pancreatic tumor incidence by 77% in mid-dose group and 100% in high-dose group. The compound also showed potential in preventing precursor lesions, with 67.6% of mice free of pancreatic intraepithelial neoplasms at 100 ppm dose.
Researchers at Thomas Jefferson University have been awarded a $100,000 grant from the W.W. Smith Charitable Trust to investigate why African-Americans respond poorly to common chemotherapeutic agents used to treat pancreatic cancer.
A UNC research team has identified RGL2 as a critical protein in the KRAS signaling pathway, which could lead to the development of effective pancreatic cancer treatments. The team's findings suggest that blocking this pathway may hold promise for halting the growth of pancreatic tumors.
Researchers at Henry Ford Hospital found stereotactic body radiotherapy (SBRT) to be an effective treatment option for inoperable pancreatic cancer patients, slowing disease progression by almost six months. SBRT provides a highly targeted cancer radiation therapy with minimal side effects.
A new study from Johns Hopkins Medicine finds that pancreatic cancers develop and spread much more slowly than previously thought. The research suggests that there is a potentially broad window for diagnosis and prevention of the disease, with an average progression time of 11.7 years.
Researchers uncovered unique genomic instability in pancreatic cancer, which drives tumor adaptation and spread. This study highlights the need for improved early diagnosis methods and targeted treatments.
A project led by Mr Hemant Kocher aims to target the stroma surrounding pancreatic cancer tumours, which is believed to drive tumour growth and prevent drug treatments from reaching the tumour. The research may lead to new drug targets for treating pancreatic cancer, a disease with poor survival rates.
Researchers at Rice University are testing a nanoparticle designed to diagnose and treat pancreatic cancer, which is notoriously difficult to treat with a five-year preclinical testing program funded by the National Cancer Institute.
A team of UNC scientists has received a $2,308,800 grant to develop targeted nano-particle technology for early detection and more effective treatments of pancreatic cancer. The goal is to design nanoscale metal-organic frameworks capable of carrying imaging and therapeutic cargoes or multiple drugs.
A study found that nearly three-quarters of pancreatic cancer tumours have high levels of a protein called P110γ, which could provide a new target for treatments. Blocking this protein stopped cancer cell growth in laboratory experiments.
A study published in JAMA found that gemcitabine was not superior to fluorouracil plus folinic acid in terms of overall survival for patients with resected pancreatic cancer. The study included 1,088 patients and showed no significant difference in survival estimates between the treatment groups.
A study by UCLA researchers found that pancreatic cancer cells can metabolize fructose to generate nucleic acids, driving cell division and proliferation. The study suggests that high fructose corn syrup consumption may be linked to increased cancer risk, highlighting the need for reduced refined sugar intake.
Researchers developed functional magnetic resonance imaging (MRI) to evaluate pancreatic cancer models, using diffusion-weighted and transcatheter intraarterial perfusion MRI to differentiate living from dead cells. This non-invasive method may replace invasive techniques like biopsy or necropsy for assessing therapeutic efficacy.
A six-gene signature associated with metastatic disease has been identified in patients with pancreatic cancer, enabling earlier prediction of survival prognosis and potential therapeutic targets. This finding may inform treatment decisions and improve patient outcomes.
A new study finds that endoscopic ultrasound (EUS) is associated with improved outcomes in patients with localized pancreatic cancer. EUS evaluation was found to improve overall survival, possibly due to earlier cancer detection and more selective surgery. The study analyzed a large population-based cancer registry and demonstrated the...
Researchers at Heidelberg University Hospital found a promising new treatment for pancreatic cancer combining sorafenib with sulforaphane, an anti-cancer compound in broccoli. The combination treatment inhibits resistant tumor stem cells and blocks metastasis without causing additional side effects.
Pancreatic researchers have developed a method to distinguish between pre-cancerous and benign cysts using glycans. This could lead to fewer deaths from pancreatic cancer by detecting and removing pre-cancerous cysts. The study's findings offer new hope for early detection and treatment of the disease.
Researchers at the University of Pennsylvania School of Medicine have made significant progress in treating metastatic breast cancer, using a targeted immunotherapy approach that boosts the effectiveness of a therapeutic vaccine. The treatment has shown rapid and marked loss of Tregs without toxicity, resulting in stabilization of dise...
Researchers found that patients with pancreatic adenocarcinoma whose tumors respond most to preoperative chemotherapy and radiation survive four times as long, on average, than those who respond least. The study suggests that identifying molecular factors associated with a major pathologic response could lead to important progress in t...
Researchers found that pancreatic cancer patients with circulating tumor cells tend to have worse outcomes, and some types of cells may predict poorer survival. The presence of MUC1 protein-expressing circulating tumor cells is particularly associated with shorter overall survival.
Research from UT Southwestern Medical Center found that heavy alcohol use and binge drinking significantly increase the risk of pancreatic cancer in men. Men who consumed large amounts of alcohol were up to 6 times more likely to develop pancreatic cancer compared to those who drank little or no alcohol.
Researchers confirm a link between pancreatic cancer and inflammatory bowel disease, finding that EUS is as effective as surgery in treating pancreatic pseudocysts. Additionally, studies suggest that intra-abdominal fat can predict survival in pancreatic cancer patients, while new technology shows promise for improved surgical procedures.
Researchers at UNC identified a molecular marker of pancreatic cancer that may help diagnose the disease earlier. A specific form of a protein called palladin is produced in large amounts in tumor-associated fibroblasts surrounding a pancreatic tumor, making it a potential diagnostic tool.
A systematic review of 111 studies involving 4,394 patients found that a third could undergo resection after neoadjuvant therapy, with similar survival rates to those judged resectable before treatment. The study suggests including locally advanced/unresectable tumors in neoadjuvant protocols.
Researchers investigated COX-2 expression as a prognostic factor in pancreatic cancer, finding no significant correlation between high COX-2 levels and survival rates. High histological grade and nodal involvement remained key predictors of shorter survival.
A study of 145 patients with branch duct IPMN found that prognosis depends on presence of intra- or extra-pancreatic cancer. This suggests it's essential to assess for these conditions when examining IPMN patients.
A research team from Japan has discovered that inhibiting IGF-IR activity decreases proliferation and motility of pancreatic cancer cell lines. This finding suggests a potential new approach for treating pancreatic cancer.
A global consortium has cataloged genetic changes of 50 common cancers, making it possible to sequence partial or full genomes as part of clinical evaluation. This will enable targeted treatments and help understand why some treatments work and others do not.
Jonathan Brody has received a 2010 Pancreatic Cancer Action Network-AACR Career Development Award to support his innovative research on pancreatic cancer. He aims to extend funding and translate his findings into clinical settings.
Researchers at UT Southwestern Medical Center found that a synthetic compound called JP1201, mimicking the action of a 'death-promoting' protein, can enhance chemotherapy's efficacy and prolong life in mice with pancreatic cancer. The study demonstrates promising results for potential therapies against this devastating disease.
Researchers have developed a novel interventional radiology treatment called nanoembolization, which uses gold nanoparticles to kill cancer cells. The treatment involves injecting the nanoparticles directly into tumors via an artery near the tumor site, bypassing scar tissue that blocks traditional treatments.
Researchers at the Mayo Clinic have found that PKC-iota is over-produced in pancreatic cancer and is linked to poor patient survival. Genetically inhibiting PKC-iota led to a significant decrease in pancreatic tumor growth and spread in laboratory animals.
Researchers have identified four mRNA biomarkers in saliva that differentiate pancreatic cancer patients from non-cancer subjects with high sensitivity and specificity. The findings suggest a potential role for salivary diagnostics in early detection and treatment of pancreatic cancer, a leading cause of cancer death.
A study by UCLA's Jonsson Comprehensive Cancer Center found that specific histone modifications can predict prognosis and response to treatment in pancreatic cancer patients. The findings suggest that low levels of these modifications are associated with poor survival, while high levels may indicate a favorable response to chemotherapy.
Researchers found that obese patients with pancreatic cancer have significantly higher levels of MCP-1, a chemokine associated with inflammation, compared to non-obese patients with the same condition. Inflammation has been shown to contribute to tumor progression in pancreatic ductal adenocarcinoma.
A new study by Northwestern University's Feinberg School of Medicine and the American College of Surgeons found that community hospitals can offer safe surgical options for certain types of cancer surgeries. Younger patients with few pre-existing illnesses have similar survival rates at both community hospitals and specialized cancer c...
Researchers at University of California, San Diego have identified a signaling protein called RON that helps pancreatic cancer cells survive and resist chemotherapy. The study provides new insights into pancreatic cancer development and suggests combining RON-targeted therapy with other treatments to combat tumor resistance.
The Pancreatic Cancer Action Network and AACR awarded Zeshaan Rasheed a $600,000 grant to study cancer stem cells in pancreatic adenocarcinoma. The grant aims to develop novel therapies targeting cancer stem cell growth and spread.
A paracrine pathway involving glial cell-derived neurotrophic factor (GDNF) regulates the migration of pancreatic cancer cells along nerves. The pathway plays a crucial role in preventing nerve invasion and has potential as an adjuvant therapy for pancreatic cancer.
A new study published in the Journal of the National Cancer Institute found that having multiple family members with pancreatic cancer significantly increases an individual's risk of developing the disease. Relatives with a relative diagnosed under 50 years old are at a ninefold higher risk than the general population.
A study at Washington University School of Medicine identified mesothelin as a marker for pancreatic tumors, suggesting its potential use in immune therapy against the disease. Mesothelin levels in the blood were found to be significantly higher in patients with pancreatic adenocarcinoma compared to healthy individuals.
A large cohort study found that patients with type 2 diabetes mellitus have a threefold increased risk of pancreatic cancer and a twofold increased risk of gallbladder and extrahepatic biliary cancers compared to non-diabetic controls. This is the first comprehensive assessment of the risk for these cancers in type 2 DM patients.
Researchers have developed tumor-penetrating microparticles (TPM) to deliver drugs more effectively, targeting both rapid- and slow-growing tumors. TPM has shown promise in treating pancreatic cancer by breaking through barriers and delivering highly concentrated drug doses.
Scientists at MIT have discovered that tumors can arise from different types of cells in the pancreas, depending on whether they are injured or inflamed. This finding could lead to new treatments and early diagnosis methods for pancreatic cancer.
A recent study published by Henry Ford Hospital contradicts previous research suggesting hepatitis B infection increases the risk of pancreatic cancer. Age is found to be the only significant predictor of pancreatic cancer in patients infected with hepatitis B.
Researchers discover a drug that inhibits TAK-1 enzyme, making pancreatic cancer cells sensitive to chemotherapy. The combination of the drug with classic anti-cancer drugs shows significant tumor reduction and increased survival rates in mice.
The Bernard Lee Schwartz Foundation has established a new three-year Research Scholar Award for pancreatic cancer research, providing funding and protected time for a young investigator. The award aims to advance knowledge of early detection and treatment of pancreatic cancer.
Research on endothelin-1 (ET-1) reveals its role in promoting fibrosis in pancreatic stellate cells. ET-1 stimulates cell activation, leading to inflammation and fibrosis. Inhibition of ET-1 may offer a novel approach to treating chronic pancreatitis and pancreatic cancer.
Researchers at the University of Texas M. D. Anderson Cancer Center have identified four microRNAs that can accurately detect pancreatic cancer and pre-invasive lesions. The study found that these microRNAs are overexpressed in precursor lesions leading to full-blown pancreatic cancer, offering a promising approach for early detection.
Researchers at Case Western Reserve University School of Medicine have discovered the prion protein as a novel biomarker for pancreatic cancer. The study found that the prion binds to filamin A in human pancreatic cancer cells, disrupting cell organization and signaling, and leading to aggressive tumor growth.
A new diagnostic tool developed by Van Andel Research Institute has shown promising results in detecting pancreatic cancer more effectively. The method studies carbohydrate structures in the bloodstream and could lead to the development of blood tests that can detect cancer.